| Literature DB >> 31845170 |
Daniel Schuch da Silva1, Mayara Sandrielly Pereira Soares2, Franciele Martini3, Ana Paula Pesarico3, Bruna da Silveira de Mattos2, Anita Avila de Souza2, Cesar Emiliano Hoffman da Silva1, João Luis Rheingantz Scaini4, Karina Dos Santos Machado4, Cristina Wayne Nogueira3, Roselia Maria Spanevello5, Wilson Cunico6.
Abstract
This work evaluated the in vitro effect of thiazolidin-4-ones on the activity of AChE (total and isoforms) isolated from the cerebral cortex, hippocampus, and lymphocytes. Kinetic parameters were evaluated and molecular docking was performed. Our results showed that thiazolidinones derived from 4-(methylthio)benzaldehyde (1) and from 4-(methylsulfonyl)benzaldehyde (2) were capable of inhibiting the AChE activity in vitro. Three compounds, two with a propylpiperidine (1b and 2b) moiety and one with a 3-(diethylamino)propyl (1c) moiety showed IC50 values of 13.81 μM, and 3.13 μM (1b), 55.36 μM and 44.33 μM (1c) for cerebral cortex and hippocampus, respectively, and 3.11 μM for both (2b). Enzyme kinetics revealed that the type of AChE inhibition was mixed. Compound 1b inhibited the G1 and G4 AChE isoforms, while compounds 1c and 2b selectively inhibited the G4 isoform. Molecular docking showed a possible three-dimensional fit into the enzyme. Our findings showed that these thiazolidin-4-ones, especially those containing the propylpiperidine core, have a potential cholinesterase inhibitory activity and can be considered good candidates for future Alzheimer's therapy.Entities:
Keywords: 1,3-Thiazolidin-4-ones; AChE isoforms; Acetylcholinesterase; Cerebral cortex; Hippocampus
Year: 2019 PMID: 31845170 DOI: 10.1007/s11064-019-02929-8
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 3.996